Table 2.
Effects of RA on ischemia-reperfused diabetic rats: a dose–response study
| Group | Survival (# rats) | Neurological scores (median/range) | Blood glucose (mM) | Infarct volume (%) | Brain water content (%) |
|---|---|---|---|---|---|
| Control |
10/10 |
— |
5.2 ± 0.6 |
— |
76.8 ± 0.3 |
| Diabetic |
10/10 |
— |
19.1 ± 2.3 |
— |
77.0 ± 0.4 |
| Vehicle |
8/10 |
4/2# |
19.8 ± 2.5 |
28.4 ± 5.3# |
79.5 ± 0.4# |
| RA 12.5 |
9/10 |
3/3 |
19.6 ± 2.6 |
24.5 ± 5.4 |
79.3 ± 0.4 |
| RA 25 |
9/10 |
3/4* |
19.5 ± 2.4 |
21.8 ± 5.7* |
79.0 ± 0.5* |
| RA 50 |
10/10 |
2/3** |
20.1 ± 2.7 |
19.7 ± 5.2** |
78.9 ± 0.3** |
| RA 100 |
10/10 |
2/3** |
19.7 ± 2.6 |
16.5 ± 4.4** |
78.7 ± 0.4** |
| RA 200 | 10/10 | 2/3** | 19.6 ± 2.8 | 15.5 ± 3.2** | 78.6 ± 0.5** |
Data are means ± SD, with n = 10 for each group. RA at doses ranging from 12.5 to 200 mg/kg, was administered intravenously 30 minutes after cerebral I/R. RA indicates rosmarinic acid, Control indicates non-diabetic rats. #P <0.01 vs. Diabetic group; *P <0.05, **P <0.01 vs Vehicle-treated group. Cerebral infarct volume and brain water content between groups were compared using one-way ANOVA followed by Dunnett's test. Neurological scores between groups were compared using a nonparametric test.